Live Breaking News & Updates on Now Under Way

Stay updated with breaking news from Now under way. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Millionenprojekte: So geht es mit den Großbaustellen in Bad Salzuflen voran | Lokale Nachrichten aus Bad Salzuflen

+ data.text + + + + ; //jQuery( #modul-autor ).append(html); if (jQuery( #modul-autor ).html() != ) { jQuery( #modul-autor ).removeClass( hidden ); initMasonry(); setTimeout(function(){ initMasonry(); }, 3000); jQuery( .content-right-col .autor-tooltip-description ).find( .autor-description ).expander({ slicePoint: 80, expandPrefix: , expandText: [mehr] , userCollapseText: }); posMediaItems(); } } }); Tipped.create( #article-author-2027 , { padding: false, skin: light , radius: false, position: bottomleft , size: large , ajax: { url: / em cms/globals/aauth.php?autor=2027&aktion=info , dataType: json , success: function(data, textStatus, jqXHR) { if(typeof data.media == undefined ) { data.media = { cached: / em daten/lz/ layout/platzhalter.png }; } var html = + + + ; if(data.social media) { var strSocialMedia = data.social media.sp ....

Nordrhein Westfalen , Bernd Zimmermann , Nbg Salzuflen , Alexandra Schaller , School Wasserfuhr , Works In Nbg Salzuflen , From Nbg , City Of Nbg , Fire Brigade Nbg , For Nbg , Cold Season , Demolition Work , Target Area , Northern Part , School According , Million Euro , Euro Also , New Architecture , Town Hall , Costs Are , Now Under Way , Wirtschaftlichkeitsuntersuchung Should , According To Bernd Zimmermann , Winner Will Be Awo , New Building , Bernd Zimmermann Prepared With ,

Prelude Therapeutics Announces First Quarter 2021 Financial Results and Operations Update


Published: May 11, 2021
- Enrollment Now Underway in Multiple Solid Tumor and Hematologic Malignancy Expansion Cohorts in Phase 1 Trial of Oral PRMT5 Inhibitor PRT543 -
- Initial Clinical Data Readouts for Lead Oral PRMT5 Inhibitors PRT543 and PRT811 Expected in 2H21 -
- Dose Escalation Ongoing in Phase 1 Trial of Oral MCL1 Inhibitor PRT1419, with Dose Expansion Cohorts on Track to be Added in 2H21 -
WILMINGTON, Del., May 11, 2021 (GLOBE NEWSWIRE) Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced its financial results for the first quarter ended March 31, 2021 and provided an update on recent clinical and development pipeline progress. ....

United States , Kris Vaddi , Deborah Elson , Melissa Forst , Exchange Commission , Development Rd Expenses , American Association For Cancer Research , Company Phase , Prelude Therapeutics Inc , Drug Administration , Now Under Way , Multiple Solid Tumor , Hematologic Malignancy Expansion Cohorts , Clinical Data Readouts , Lead Oral , Escalation Ongoing , Dose Expansion Cohorts , Chief Executive , Data Featured , American Association , Cancer Research , Annual Meeting , Prelude Therapeutics , Expansion Cohorts Remain , Planned Dose Expansion , Combination Cohorts Expected ,